Dynamic contrast-enhanced breast MRI is a useful tool in aiding detection of residual disease following excisional biopsy for breast cancer.
Dynamic contrast-enhanced breast MRI aids physicians in predicting residual disease after an excisional biopsy for breast cancer has been performed, according to a study published in the American Journal of Roentgenology.
Researchers from South Korea undertook a study to assess the diagnostic performance of breast MRIs in evaluating if there remained any residual breast cancer in patients who had undergone an excisional biopsy. The researchers analyzed the MRI findings of 203 patients who, between January 2007 and December 2011, had:
The enhancement patterns were classified into four categories: no enhancement (P1), thin regular rim enhancement (P2), thick or irregular rim enhancement (P3), and nodular or non-mass-like enhancement (P4) around the postoperative sites. The enhancement kinetics were assessed as persistent, plateau, and washout pattern.
The results showed that among the 207 breast MRI examinations of the 203 patients, 144 breasts showed signs of residual breast cancer at histopathologic examination after definitive surgery.
When the enhancements P1 and P2 were considered to be negative for residual cancer and P3 and P4 were considered positive, the sensitivity, specificity, positive and negative predictive values, and accuracy were 79.9 percent, 73.0 percent, 87.1 percent, 61.3 percent, and 77.8 percent, respectively.
The specificity and positive predictive value improved to 90.5 percent and 91.7 percent, when analyzed with washout enhancement kinetics as another positive finding for residual cancer.
“Although the overlapping features of the postsurgical changes and malignant lesions remain as the limitations, dynamic contrast-enhanced breast MRI is a useful tool for residual disease prediction after excisional biopsy for breast cancer,” the authors wrote. “Combined use of morphologic and kinetic evaluation parameters improved the diagnostic performance.”
The authors recommended that MRI not be unreasonably delayed after excisional biopsy considering the risk of prolonging definitive surgery.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.